Dexasone
Plasma Cell Myeloma
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07600151CT.gov Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07609706CT.gov A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | — | Not Yet Recruiting | — | — | — |
NCT06948084CT.gov Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse | — | Not Yet Recruiting | — | — | — |
NCT07614360CT.gov Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07637578CT.gov A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07479979CT.gov Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07285239CT.gov Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07555938CT.gov Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | — | Recruiting | — | — | — |
NCT07601100CT.gov Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07463807CT.gov Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | — | Not Yet Recruiting | — | — | — |
Show 944 more trialsShow fewer
NCT07624513CT.gov Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07428369CT.gov A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | — | Withdrawn | — | — | — |
NCT07569757CT.gov Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07637526CT.gov Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07649525CT.gov Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | — | Not Yet Recruiting | — | — | — |
NCT07341867CT.gov Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | — | Not Yet Recruiting | — | — | — |
NCT07247097CT.gov ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07227311CT.gov A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
NCT07082270CT.gov Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT07382739CT.gov A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" | — | Recruiting | — | — | — |
NCT07452198CT.gov A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07391657CT.gov A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | — | Recruiting | — | — | — |
NCT07284758CT.gov A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07280013CT.gov A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | — | Recruiting | — | — | — |
NCT07348393CT.gov A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Not Yet Recruiting | — | — | — |
NCT07334535CT.gov Isa-VRD in TIE HRMM | — | Not Yet Recruiting | — | — | — |
NCT07579234CT.gov A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07096778CT.gov Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07095452CT.gov A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT07222761CT.gov A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
NCT07297329CT.gov A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT06932562CT.gov A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT07032714CT.gov Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07107529CT.gov Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | — | Recruiting | — | — | — |
NCT06910124CT.gov Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | — | Recruiting | — | — | — |
NCT06827860CT.gov Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | — | Recruiting | — | — | — |
NCT07138209CT.gov A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07413809CT.gov Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen | — | Recruiting | — | — | — |
NCT06988488CT.gov A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07101445CT.gov Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial | — | Recruiting | — | — | — |
NCT06997081CT.gov ERd Combination Treatment in Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT07018050CT.gov Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | — | Recruiting | — | — | — |
NCT07210047CT.gov Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | — | Enrolling By Invitation | — | — | — |
NCT06832865CT.gov ELISA in Relapsed/Refractory MM | — | Recruiting | — | — | — |
NCT07085728CT.gov Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure | — | Active Not Recruiting | — | — | — |
NCT06974786CT.gov Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | — | Recruiting | — | — | — |
NCT06348108CT.gov Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07099391CT.gov A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06953960CT.gov A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | — | Recruiting | — | — | — |
NCT06918002CT.gov Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients | — | Recruiting | — | — | — |
NCT06892522CT.gov A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | — | Recruiting | — | — | — |
NCT07045909CT.gov Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | — | Recruiting | — | — | — |
NCT06581848CT.gov Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). | — | Active Not Recruiting | — | — | — |
NCT07015021CT.gov The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients | — | Not Yet Recruiting | — | — | — |
NCT06947083CT.gov Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | — | Recruiting | — | — | — |
NCT06627751CT.gov Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease | — | Recruiting | — | — | — |
NCT06931704CT.gov Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | — | Not Yet Recruiting | — | — | — |
NCT06232044CT.gov Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06622005CT.gov SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06793475CT.gov Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease | — | Recruiting | — | — | — |
NCT06682637CT.gov Melflufen for Elderly Patients With Relapsed Myeloma | — | Withdrawn | — | — | — |
NCT06785415CT.gov Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06356571CT.gov A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06615479CT.gov A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | — | Recruiting | — | — | — |
NCT06924424CT.gov Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06879379CT.gov KPD Consolidation After ASCT in NDMM Patients | — | Recruiting | — | — | — |
NCT06799676CT.gov A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT06799026CT.gov A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06015542CT.gov Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | — | Recruiting | — | — | — |
NCT06855121CT.gov The Norwegian Immunotherapy in Multiple Myeloma Study | — | Recruiting | — | — | — |
NCT06742138CT.gov To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT06711705CT.gov Elranatamab in Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06679101CT.gov A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | — | Recruiting | — | — | — |
NCT05272826CT.gov Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients | — | Recruiting | — | — | — |
NCT06768489CT.gov A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma | — | Recruiting | — | — | — |
NCT05846880CT.gov VitD3 Supplementation in Patients With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06645678CT.gov Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06142396CT.gov Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure | — | Recruiting | — | — | — |
NCT06518551CT.gov Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | — | Recruiting | — | — | — |
NCT06351644CT.gov ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT06592222CT.gov A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies | — | Completed | — | — | — |
NCT06413498CT.gov A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06433947CT.gov Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06577025CT.gov A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04876248CT.gov Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT06169215CT.gov Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06207799CT.gov Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT06353022CT.gov Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06505369CT.gov Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT06508983CT.gov A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT06409702CT.gov Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | — | Recruiting | — | — | — |
NCT05922501CT.gov Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06158841CT.gov Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06232707CT.gov A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Withdrawn | — | — | — |
NCT06216158CT.gov Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06464991CT.gov A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | — | Recruiting | — | — | — |
NCT06484829CT.gov Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06138275CT.gov Elranatamab in R/R Multiple Myeloma | — | Recruiting | — | — | — |
NCT06203912CT.gov Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06042725CT.gov MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | — | Recruiting | — | — | — |
NCT05050305CT.gov Marizomib Central Nervous System (CNS) | — | Withdrawn | — | — | — |
NCT06163898CT.gov A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT06121843CT.gov A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06215118CT.gov A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | — | Recruiting | — | — | — |
NCT05896228CT.gov Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06152575CT.gov MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | — | Recruiting | — | — | — |
NCT06208150CT.gov A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | — | Recruiting | — | — | — |
NCT05820763CT.gov Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | — | Withdrawn | — | — | — |
NCT06163040CT.gov A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | — | Completed | — | — | — |
NCT05572229CT.gov Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | — | Recruiting | — | — | — |
NCT05981209CT.gov Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | — | Active Not Recruiting | — | — | — |
NCT05231629CT.gov Sequential Therapy in Multiple Myeloma Guided by MRD Assessments | — | Recruiting | — | — | — |
NCT06055075CT.gov A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT06106945CT.gov AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | — | Recruiting | — | — | — |
NCT05911321CT.gov Isa-Pom-Dex in Elderly/Frail Subjects With RRMM | — | Active Not Recruiting | — | — | — |
NCT06158269CT.gov DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | — | Recruiting | — | — | — |
NCT06158412CT.gov All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05583617CT.gov A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06246162CT.gov Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma | — | Recruiting | — | — | — |
NCT06119685CT.gov IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | — | Recruiting | — | — | — |
NCT05972135CT.gov Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | — | Recruiting | — | — | — |
NCT06140966CT.gov Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06045806CT.gov A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT05257083CT.gov A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06057402CT.gov Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | — | Recruiting | — | — | — |
NCT06050512CT.gov Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT05849610CT.gov Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05730036CT.gov A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT03759093CT.gov CURATE.AI Optimized Modulation for Multiple Myeloma | — | Unknown | — | — | — |
NCT06504524CT.gov A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US | — | Completed | — | — | — |
NCT05776979CT.gov Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT05927571CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | — | Recruiting | — | — | — |
NCT05573802CT.gov A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05909826CT.gov Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM | — | Not Yet Recruiting | — | — | — |
NCT05690984CT.gov Elimination of Minimal Residual Disease After Transplant | — | Active Not Recruiting | — | — | — |
NCT05827016CT.gov A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05714839CT.gov A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | — | Recruiting | — | — | — |
NCT05932290CT.gov A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05789303CT.gov Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05857982CT.gov Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT05850286CT.gov A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities | — | Active Not Recruiting | — | — | — |
NCT05804032CT.gov Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT05704049CT.gov A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05669989CT.gov International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | — | Active Not Recruiting | — | — | — |
NCT05860036CT.gov A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05572515CT.gov A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05719701CT.gov Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT05530421CT.gov Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05675319CT.gov Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy | — | Terminated | — | — | — |
NCT05651932CT.gov A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05641324CT.gov A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | — | Terminated | — | — | — |
NCT05560399CT.gov A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05665140CT.gov Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT05590377CT.gov A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT05647512CT.gov Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | — | Withdrawn | — | — | — |
NCT05434689CT.gov COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | — | Active Not Recruiting | — | — | — |
NCT05556616CT.gov A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | — | Terminated | — | — | — |
NCT05552976CT.gov A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | — | Active Not Recruiting | — | — | — |
NCT05344833CT.gov Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma | — | Recruiting | — | — | — |
NCT05438043CT.gov A Study of Daratumumab | — | Recruiting | — | — | — |
NCT05527340CT.gov Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | — | Active Not Recruiting | — | — | — |
NCT05675449CT.gov A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05432414CT.gov PVd Versus Vd in NDMM Patients With RI | — | Unknown | — | — | — |
NCT04756401CT.gov Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06209606CT.gov Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | — | Recruiting | — | — | — |
NCT05695508CT.gov GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | — | Recruiting | — | — | — |
NCT05091372CT.gov Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05493618CT.gov Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | — | Withdrawn | — | — | — |
NCT05363111CT.gov Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05623020CT.gov A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | — | Recruiting | — | — | — |
NCT04933539CT.gov Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05552222CT.gov A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05581875CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | — | Not Yet Recruiting | — | — | — |
NCT05259839CT.gov A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05372354CT.gov A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05455320CT.gov A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | — | Active Not Recruiting | — | — | — |
NCT05478993CT.gov Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement | — | Unknown | — | — | — |
NCT05514990CT.gov Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | — | Active Not Recruiting | — | — | — |
NCT05565391CT.gov A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05561049CT.gov Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT05408026CT.gov Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | — | Withdrawn | — | — | — |
NCT05558319CT.gov NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | — | Not Yet Recruiting | — | — | — |
NCT05497804CT.gov Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | — | Active Not Recruiting | — | — | — |
NCT05519085CT.gov A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
NCT05027594CT.gov Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT05243797CT.gov Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT07150104CT.gov Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | — | Active Not Recruiting | — | — | — |
NCT05137054CT.gov A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | — | Recruiting | — | — | — |
NCT05392946CT.gov Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | — | Active Not Recruiting | — | — | — |
NCT05469893CT.gov Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | — | Recruiting | — | — | — |
NCT05495620CT.gov Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT05422027CT.gov Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05208307CT.gov Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | — | Recruiting | — | — | — |
NCT07150091CT.gov Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | — | Active Not Recruiting | — | — | — |
NCT05900882CT.gov SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | — | Recruiting | — | — | — |
NCT05722405CT.gov Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT05183139CT.gov A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT05405166CT.gov SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM | — | Active Not Recruiting | — | — | — |
NCT04975997CT.gov Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT06255847CT.gov Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM | — | Unknown | — | — | — |
NCT05288062CT.gov Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | — | Terminated | — | — | — |
NCT05308654CT.gov A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | — | Active Not Recruiting | — | — | — |
NCT05199311CT.gov Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | — | Recruiting | — | — | — |
NCT04700176CT.gov A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT05298683CT.gov A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | — | Unknown | — | — | — |
NCT05289492CT.gov Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT05243342CT.gov A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05170789CT.gov Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT05028348CT.gov A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05280275CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | — | Unknown | — | — | — |
NCT05147493CT.gov A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | — | Unknown | — | — | — |
NCT05123131CT.gov Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04912427CT.gov Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease | — | Terminated | — | — | — |
NCT05317416CT.gov Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | — | Active Not Recruiting | — | — | — |
NCT05145400CT.gov Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT03941860CT.gov Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | — | Completed | — | — | — |
NCT06956170CT.gov All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04941937CT.gov Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM | — | Unknown | — | — | — |
NCT04895410CT.gov Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma | — | Terminated | — | — | — |
NCT04835129CT.gov Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05032820CT.gov Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | — | Completed | — | — | — |
NCT04843579CT.gov Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT04942067CT.gov APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT05228470CT.gov A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT05060627CT.gov Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | — | Active Not Recruiting | — | — | — |
NCT04998786CT.gov A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." | — | Active Not Recruiting | — | — | — |
NCT04667663CT.gov CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. | — | Active Not Recruiting | — | — | — |
NCT04223661CT.gov Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | — | Withdrawn | — | — | — |
NCT04896658CT.gov Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04925193CT.gov Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05182073CT.gov FT576 in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT04892446CT.gov Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04240054CT.gov Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency | — | Recruiting | — | — | — |
NCT05509374CT.gov Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone | — | Unknown | — | — | — |
NCT04302324CT.gov A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab | — | Active Not Recruiting | — | — | — |
NCT05090566CT.gov MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | — | Terminated | — | — | — |
NCT04891809CT.gov Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM | — | Active Not Recruiting | — | — | — |
NCT05052970CT.gov Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM | — | Unknown | — | — | — |
NCT05083169CT.gov A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05014412CT.gov A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment | — | Completed | — | — | — |
NCT05020236CT.gov A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | — | Recruiting | — | — | — |
NCT04956302CT.gov Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT05050097CT.gov A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04973605CT.gov A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | — | Recruiting | — | — | — |
NCT04782687CT.gov Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04923893CT.gov A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | — | Active Not Recruiting | — | — | — |
NCT04717700CT.gov Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | — | Active Not Recruiting | — | — | — |
NCT04883242CT.gov Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06868654CT.gov China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06868667CT.gov Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04989140CT.gov Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide | — | Unknown | — | — | — |
NCT04910568CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04751877CT.gov Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | — | Active Not Recruiting | — | — | — |
NCT04653246CT.gov Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | — | Active Not Recruiting | — | — | — |
NCT04939142CT.gov A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT04891744CT.gov Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | — | Unknown | — | — | — |
NCT04355039CT.gov INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT04939844CT.gov REST - Replacing Steroids in the Transplant Ineligble | — | Completed | — | — | — |
NCT04892264CT.gov Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | — | Terminated | — | — | — |
NCT04877275CT.gov ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | — | Unknown | — | — | — |
NCT04822337CT.gov Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04764942CT.gov Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | — | Active Not Recruiting | — | — | — |
NCT04756726CT.gov Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04818372CT.gov Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | — | Unknown | — | — | — |
NCT04813653CT.gov Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells | — | Completed | — | — | — |
NCT04674514CT.gov APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04802356CT.gov Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT04790474CT.gov Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib | — | Active Not Recruiting | — | — | — |
NCT04965155CT.gov A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) | — | Active Not Recruiting | — | — | — |
NCT04661137CT.gov A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | — | Suspended | — | — | — |
NCT04722146CT.gov A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04824794CT.gov GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | — | Terminated | — | — | — |
NCT04392037CT.gov Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone | — | Active Not Recruiting | — | — | — |
NCT04762745CT.gov The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04643002CT.gov Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | — | Recruiting | — | — | — |
NCT05236621CT.gov A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04649060CT.gov Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04445701CT.gov Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04407442CT.gov Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | — | Terminated | — | — | — |
NCT04508790CT.gov Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT04570631CT.gov Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04519476CT.gov Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | — | Unknown | — | — | — |
NCT04009109CT.gov Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | — | Active Not Recruiting | — | — | — |
NCT04614636CT.gov FT538 in Subjects With Advanced Hematologic Malignancies | — | Terminated | — | — | — |
NCT04484623CT.gov Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04483739CT.gov Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) | — | Active Not Recruiting | — | — | — |
NCT04287855CT.gov Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04513639CT.gov The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | — | Recruiting | — | — | — |
NCT04458831CT.gov A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03841565CT.gov Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT04191616CT.gov Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet | — | Completed | — | — | — |
NCT04277845CT.gov Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT03720041CT.gov Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT04430894CT.gov KRDI in Transplant-Eligible MM | — | Active Not Recruiting | — | — | — |
NCT04150965CT.gov Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | — | Terminated | — | — | — |
NCT04405167CT.gov Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | — | Terminated | — | — | — |
NCT03959358CT.gov A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | — | Completed | — | — | — |
NCT04414475CT.gov A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | — | Recruiting | — | — | — |
NCT04392648CT.gov A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Withdrawn | — | — | — |
NCT04270409CT.gov Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04181827CT.gov A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04196491CT.gov A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | — | Completed | — | — | — |
NCT04176718CT.gov Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | — | Active Not Recruiting | — | — | — |
NCT04246047CT.gov Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04352205CT.gov Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | — | Terminated | — | — | — |
NCT04162210CT.gov Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04108195CT.gov A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04280328CT.gov Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04119336CT.gov Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | — | Terminated | — | — | — |
NCT04268498CT.gov A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04113018CT.gov Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04163107CT.gov Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04091126CT.gov Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04151667CT.gov Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04174196CT.gov A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | — | Active Not Recruiting | — | — | — |
NCT04133636CT.gov A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03683277CT.gov IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic | — | Terminated | — | — | — |
NCT04052880CT.gov Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | — | Active Not Recruiting | — | — | — |
NCT04028115CT.gov Bone Healing During Ninlaro Exposure | — | Completed | — | — | — |
NCT03993912CT.gov Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy | — | Active Not Recruiting | — | — | — |
NCT03909412CT.gov Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma | — | Recruiting | — | — | — |
NCT04136756CT.gov NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT04126200CT.gov Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03989414CT.gov A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | — | Active Not Recruiting | — | — | — |
NCT03608501CT.gov A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation | — | Withdrawn | — | — | — |
NCT04217967CT.gov Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | — | Completed | — | — | — |
NCT03376477CT.gov Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission | — | Terminated | — | — | — |
NCT04094961CT.gov Ixazomib + Pomalidomide + Dexamethasone In MM | — | Active Not Recruiting | — | — | — |
NCT03934684CT.gov Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03944057CT.gov A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03702725CT.gov Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04071457CT.gov S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | — | Active Not Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT04045795CT.gov Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03606577CT.gov An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT03984097CT.gov A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | — | Completed | — | — | — |
NCT03836014CT.gov Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04025450CT.gov Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT03798678CT.gov CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03942224CT.gov Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04124497CT.gov A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT04096066CT.gov A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | — | Active Not Recruiting | — | — | — |
NCT03815279CT.gov A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | — | Enrolling By Invitation | — | — | — |
NCT03856112CT.gov Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03871829CT.gov Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab | — | Terminated | — | — | — |
NCT03657420CT.gov Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03859427CT.gov A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03729804CT.gov Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | — | Active Not Recruiting | — | — | — |
NCT03903406CT.gov Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study | — | Unknown | — | — | — |
NCT03785184CT.gov A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy | — | Withdrawn | — | — | — |
NCT03829020CT.gov Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03651128CT.gov Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03896737CT.gov Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara | — | Active Not Recruiting | — | — | — |
NCT03732703CT.gov Myeloma-Developing Regimens Using Genomics (MyDRUG) | — | Completed | — | — | — |
NCT03908138CT.gov RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT03952091CT.gov TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03828292CT.gov An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | — | Completed | — | — | — |
NCT03733691CT.gov Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | — | Terminated | — | — | — |
NCT03500445CT.gov Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03756896CT.gov Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03701321CT.gov Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03748953CT.gov Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | — | Completed | — | — | — |
NCT03763162CT.gov Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03607643CT.gov A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | — | Unknown | — | — | — |
NCT03713294CT.gov Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04065308CT.gov Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma | — | Unknown | — | — | — |
NCT03773107CT.gov LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03829371CT.gov STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | — | Active Not Recruiting | — | — | — |
NCT03669445CT.gov Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma | — | Unknown | — | — | — |
NCT03710603CT.gov Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03746652CT.gov Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT03227432CT.gov An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03715478CT.gov Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | — | Active Not Recruiting | — | — | — |
NCT03792620CT.gov Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation | — | Unknown | — | — | — |
NCT03582033CT.gov A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT03605719CT.gov Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03539744CT.gov A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. | — | Active Not Recruiting | — | — | — |
NCT03742297CT.gov Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | — | Active Not Recruiting | — | — | — |
NCT03617731CT.gov Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | — | Active Not Recruiting | — | — | — |
NCT03567616CT.gov A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03590652CT.gov Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03411031CT.gov Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | — | Terminated | — | — | — |
NCT03520985CT.gov Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03544281CT.gov To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03731832CT.gov Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03457142CT.gov Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy | — | Terminated | — | — | — |
NCT03639610CT.gov PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function | — | Terminated | — | — | — |
NCT03948035CT.gov Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | — | Active Not Recruiting | — | — | — |
NCT03465540CT.gov Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | — | Terminated | — | — | — |
NCT07206810CT.gov A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT03605056CT.gov Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | — | Unknown | — | — | — |
NCT03589222CT.gov SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03506802CT.gov TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03512353CT.gov A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | — | Terminated | — | — | — |
NCT03556332CT.gov A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT03506360CT.gov Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT03031730CT.gov Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | — | Terminated | — | — | — |
NCT03376672CT.gov Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT03530683CT.gov A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | — | Terminated | — | — | — |
NCT03399539CT.gov Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT04065789CT.gov Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | — | Completed | — | — | — |
NCT03143036CT.gov Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma | — | Unknown | — | — | — |
NCT03412565CT.gov A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | — | Completed | — | — | — |
NCT03439280CT.gov A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT03481556CT.gov Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM | — | Terminated | — | — | — |
NCT03433001CT.gov A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone | — | Completed | — | — | — |
NCT03314181CT.gov A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03492138CT.gov Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03314636CT.gov Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. | — | Active Not Recruiting | — | — | — |
NCT03224507CT.gov Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma | — | Completed | — | — | — |
NCT03439293CT.gov A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03416374CT.gov A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy | — | Completed | — | — | — |
NCT03450057CT.gov Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment | — | Completed | — | — | — |
NCT03413800CT.gov Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | — | Completed | — | — | — |
NCT03256045CT.gov Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03374085CT.gov A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Terminated | — | — | — |
NCT04008888CT.gov a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients | — | Unknown | — | — | — |
NCT03100877CT.gov Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03336073CT.gov Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma | — | Unknown | — | — | — |
NCT03319667CT.gov A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Active Not Recruiting | — | — | — |
NCT03234972CT.gov A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03269136CT.gov PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03217812CT.gov A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | — | Completed | — | — | — |
NCT03030261CT.gov Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03357952CT.gov A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03173092CT.gov A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | — | Terminated | — | — | — |
NCT03287908CT.gov A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03215524CT.gov A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide | — | Completed | — | — | — |
NCT03275285CT.gov Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT04287660CT.gov Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | — | Unknown | — | — | — |
NCT03215030CT.gov A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03283046CT.gov Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03168100CT.gov 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03290950CT.gov A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03140943CT.gov Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT02951117CT.gov A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | — | Withdrawn | — | — | — |
NCT03104842CT.gov Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | — | Active Not Recruiting | — | — | — |
NCT03155100CT.gov Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines | — | Completed | — | — | — |
NCT03221634CT.gov Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | — | Withdrawn | — | — | — |
NCT03191981CT.gov Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03170882CT.gov A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | — | Completed | — | — | — |
NCT03202628CT.gov Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02780609CT.gov Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | — | Completed | — | — | — |
NCT02969837CT.gov Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | — | Completed | — | — | — |
NCT03004287CT.gov 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | — | Active Not Recruiting | — | — | — |
NCT03068351CT.gov Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | — | Completed | — | — | — |
NCT03180736CT.gov Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex | — | Completed | — | — | — |
NCT02952573CT.gov Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement | — | Terminated | — | — | — |
NCT03158688CT.gov Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT03151811CT.gov A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide | — | Terminated | — | — | — |
NCT02802163CT.gov Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | — | Withdrawn | — | — | — |
NCT03110562CT.gov Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT03169361CT.gov NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" | — | Completed | — | — | — |
NCT03136653CT.gov A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT03225417CT.gov Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | — | Active Not Recruiting | — | — | — |
NCT03150316CT.gov CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | — | Unknown | — | — | — |
NCT03117361CT.gov Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide | — | Terminated | — | — | — |
NCT03012880CT.gov Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02863991CT.gov Oral ONC201 in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02334865CT.gov SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | — | Active Not Recruiting | — | — | — |
NCT03000634CT.gov 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | — | Withdrawn | — | — | — |
NCT03029234CT.gov Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04063189CT.gov Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT03562169CT.gov The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | — | Recruiting | — | — | — |
NCT03000452CT.gov A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03104270CT.gov Combination Study for High Risk Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT02891811CT.gov Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | — | Completed | — | — | — |
NCT03015792CT.gov Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | — | Terminated | — | — | — |
NCT04243109CT.gov Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib | — | Terminated | — | — | — |
NCT02928029CT.gov Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | — | Terminated | — | — | — |
NCT03091933CT.gov Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | — | Unknown | — | — | — |
NCT03110822CT.gov A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | — | Recruiting | — | — | — |
NCT02899052CT.gov Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | — | Active Not Recruiting | — | — | — |
NCT02939183CT.gov Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03023527CT.gov Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | — | Terminated | — | — | — |
NCT02963493CT.gov A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02990338CT.gov Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02924272CT.gov Ixazomib Rollover Study | — | Completed | — | — | — |
NCT02906332CT.gov Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | — | Terminated | — | — | — |
NCT02756663CT.gov Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT02986451CT.gov Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma | — | Withdrawn | — | — | — |
NCT02917941CT.gov A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02773030CT.gov A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02605356CT.gov Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT02937571CT.gov High Dose Carfilzomib for Newly Diagnosed Myeloma | — | Completed | — | — | — |
NCT02843074CT.gov Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02902965CT.gov Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02880228CT.gov Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant | — | Completed | — | — | — |
NCT02765854CT.gov Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | — | Completed | — | — | — |
NCT02916420CT.gov Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT02726581CT.gov An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02897830CT.gov Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma | — | Terminated | — | — | — |
NCT02719613CT.gov Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | — | Completed | — | — | — |
NCT02755597CT.gov A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | — | Completed | — | — | — |
NCT02807454CT.gov A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02597062CT.gov High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT02728102CT.gov Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | — | Completed | — | — | — |
NCT02831686CT.gov A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | — | Completed | — | — | — |
NCT02718833CT.gov A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02720510CT.gov A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | — | Terminated | — | — | — |
NCT02569320CT.gov HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT02654990CT.gov Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02659293CT.gov Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02685826CT.gov A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02697344CT.gov Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT02492750CT.gov Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | — | Completed | — | — | — |
NCT02654132CT.gov An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | — | Completed | — | — | — |
NCT02406222CT.gov Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT02703779CT.gov Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT02548962CT.gov Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03440411CT.gov Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment | — | Terminated | — | — | — |
NCT02612779CT.gov A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. | — | Completed | — | — | — |
NCT02697383CT.gov Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study | — | Completed | — | — | — |
NCT02516696CT.gov BiRd vs. Rd as Initial Therapy in Multiple Myeloma | — | Terminated | — | — | — |
NCT02616640CT.gov A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02649790CT.gov Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | — | Completed | — | — | — |
NCT02655458CT.gov Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | — | Completed | — | — | — |
NCT02619682CT.gov Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02633059CT.gov Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT02547662CT.gov Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia | — | Completed | — | — | — |
NCT02461888CT.gov Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT02628704CT.gov Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | — | Withdrawn | — | — | — |
NCT02578121CT.gov UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | — | Withdrawn | — | — | — |
NCT02426723CT.gov Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | — | Completed | — | — | — |
NCT02576977CT.gov Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | — | Terminated | — | — | — |
NCT02579863CT.gov Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | — | Terminated | — | — | — |
NCT02477215CT.gov Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02586038CT.gov STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | — | Completed | — | — | — |
NCT02343042CT.gov Selinexor and Backbone Treatments of Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT02577783CT.gov PDD vs PAD to Treat Initially Diagnosed MM | — | Unknown | — | — | — |
NCT02542657CT.gov Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02513186CT.gov Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation | — | Completed | — | — | — |
NCT02412878CT.gov Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02541383CT.gov A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT02575144CT.gov GEM-CLARIDEX: Ld vs BiRd | — | Unknown | — | — | — |
NCT02384083CT.gov Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | — | Completed | — | — | — |
NCT02499081CT.gov UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | — | Completed | — | — | — |
NCT02514382CT.gov Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02412228CT.gov Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma | — | Completed | — | — | — |
NCT02440464CT.gov Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | — | Completed | — | — | — |
NCT02431208CT.gov A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT02497378CT.gov A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02389543CT.gov Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | — | Withdrawn | — | — | — |
NCT02315716CT.gov Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02331368CT.gov Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | — | Completed | — | — | — |
NCT02495922CT.gov A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma | — | Completed | — | — | — |
NCT02336815CT.gov Selinexor Treatment of Refractory Myeloma | — | Completed | — | — | — |
NCT02283775CT.gov SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients | — | Completed | — | — | — |
NCT03242460CT.gov The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT02400242CT.gov Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | — | Terminated | — | — | — |
NCT02375555CT.gov Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | — | Completed | — | — | — |
NCT02462525CT.gov Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02335983CT.gov Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT02420860CT.gov Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02312258CT.gov A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | — | Completed | — | — | — |
NCT02372240CT.gov A Study of VLX1570 and Dexamethasone in Myeloma Patients | — | Terminated | — | — | — |
NCT02410694CT.gov Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02389517CT.gov Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT02220608CT.gov Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02555839CT.gov Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice | — | Completed | — | — | — |
NCT02272803CT.gov Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan | — | Completed | — | — | — |
NCT02252172CT.gov Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT02278315CT.gov Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02203643CT.gov Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. | — | Completed | — | — | — |
NCT02332850CT.gov Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02253316CT.gov Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02573935CT.gov Clarithromycin in Multiple Myeloma Induction Therapy | — | Terminated | — | — | — |
NCT02572492CT.gov Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support | — | Unknown | — | — | — |
NCT02254551CT.gov Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02289222CT.gov 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02290431CT.gov Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02101944CT.gov Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02195479CT.gov A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT02188537CT.gov Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | — | Completed | — | — | — |
NCT02294357CT.gov Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | — | Terminated | — | — | — |
NCT01936532CT.gov Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) | — | Completed | — | — | — |
NCT02406144CT.gov Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT02424851CT.gov Optimising Renal Outcome in Myeloma Renal Failure | — | Completed | — | — | — |
NCT02219178CT.gov Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02158702CT.gov Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib | — | Unknown | — | — | — |
NCT02217163CT.gov Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma | — | Completed | — | — | — |
NCT02186834CT.gov Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02189343CT.gov Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02114502CT.gov Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | — | Withdrawn | — | — | — |
NCT02206425CT.gov Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02223598CT.gov A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies | — | Terminated | — | — | — |
NCT02136134CT.gov Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01999335CT.gov A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01889420CT.gov Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02119468CT.gov Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02199665CT.gov Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02128230CT.gov UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | — | Terminated | — | — | — |
NCT02103335CT.gov Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02100657CT.gov Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02204241CT.gov Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02185820CT.gov Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) | — | Completed | — | — | — |
NCT02176213CT.gov Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01946477CT.gov Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting | — | Completed | — | — | — |
NCT02057640CT.gov MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | — | Completed | — | — | — |
NCT01861340CT.gov Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT02095834CT.gov Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02046915CT.gov Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide | — | Completed | — | — | — |
NCT02159365CT.gov Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02046070CT.gov Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01946152CT.gov Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02077959CT.gov Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01997840CT.gov ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01794039CT.gov Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | — | Completed | — | — | — |
NCT02045017CT.gov Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | — | Completed | — | — | — |
NCT01998971CT.gov A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02036502CT.gov A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | — | Terminated | — | — | — |
NCT02004275CT.gov Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT02071888CT.gov Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | — | Completed | — | — | — |
NCT02030483CT.gov Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma | — | Terminated | — | — | — |
NCT02405364CT.gov Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction | — | Completed | — | — | — |
NCT02086552CT.gov Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01927718CT.gov Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | — | Terminated | — | — | — |
NCT01807286CT.gov Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | — | Terminated | — | — | — |
NCT01863550CT.gov Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02027220CT.gov Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT02011113CT.gov Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01985477CT.gov Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01962792CT.gov Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01919619CT.gov Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | — | Completed | — | — | — |
NCT01979276CT.gov Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma | — | Terminated | — | — | — |
NCT01989325CT.gov A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma | — | Completed | — | — | — |
NCT02002598CT.gov Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | — | Terminated | — | — | — |
NCT01881789CT.gov Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | — | Terminated | — | — | — |
NCT01903811CT.gov S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | — | Completed | — | — | — |
NCT01971658CT.gov Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) | — | Completed | — | — | — |
NCT01965353CT.gov A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01891643CT.gov PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) | — | Terminated | — | — | — |
NCT01830816CT.gov Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | — | Completed | — | — | — |
NCT02020941CT.gov Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | — | Terminated | — | — | — |
NCT01864018CT.gov Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | — | Completed | — | — | — |
NCT01720875CT.gov Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) | — | Completed | — | — | — |
NCT01969565CT.gov Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma | — | Terminated | — | — | — |
NCT01980589CT.gov A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects | — | Completed | — | — | — |
NCT01812720CT.gov Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant | — | Withdrawn | — | — | — |
NCT01818752CT.gov Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01832727CT.gov Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01897714CT.gov Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT01729091CT.gov Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01619761CT.gov NK Cells in Cord Blood Transplantation | — | Unknown | — | — | — |
NCT01850524CT.gov IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01849783CT.gov Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01827137CT.gov WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | — | Completed | — | — | — |
NCT01792102CT.gov Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | — | Unknown | — | — | — |
NCT01857115CT.gov Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) | — | Completed | — | — | — |
NCT01440582CT.gov Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | — | Completed | — | — | — |
NCT01749969CT.gov SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients | — | Completed | — | — | — |
NCT01680796CT.gov Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01754402CT.gov Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | — | Unknown | — | — | — |
NCT01734928CT.gov Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02145715CT.gov Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma | — | Unknown | — | — | — |
NCT01816971CT.gov Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01660750CT.gov A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma | — | Completed | — | — | — |
NCT01711528CT.gov Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT01645930CT.gov Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01718743CT.gov Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01755975CT.gov Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | — | Completed | — | — | — |
NCT01852799CT.gov A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01745588CT.gov Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01794507CT.gov A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | — | Completed | — | — | — |
NCT01712789CT.gov Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01668719CT.gov S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma | — | Completed | — | — | — |
NCT01794520CT.gov Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01689987CT.gov Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01731886CT.gov Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01665794CT.gov Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01592370CT.gov An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01564537CT.gov A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01660997CT.gov MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01583283CT.gov Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | — | Completed | — | — | — |
NCT01677858CT.gov A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma | — | Completed | — | — | — |
NCT01526694CT.gov Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM | — | Completed | — | — | — |
NCT01556438CT.gov Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma | — | Completed | — | — | — |
NCT01602224CT.gov A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01651039CT.gov Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01615029CT.gov Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01568866CT.gov Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT04272775CT.gov A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) | — | Terminated | — | — | — |
NCT01575925CT.gov Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) | — | Completed | — | — | — |
NCT01537861CT.gov Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01572480CT.gov Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | — | Completed | — | — | — |
NCT01246063CT.gov Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01562405CT.gov Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT01548573CT.gov Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | — | Terminated | — | — | — |
NCT01531998CT.gov Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01632150CT.gov Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01559935CT.gov Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02248428CT.gov Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT01492881CT.gov Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01374217CT.gov Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT01478581CT.gov Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01555281CT.gov Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | — | Terminated | — | — | — |
NCT01497093CT.gov Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01522872CT.gov Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT01541332CT.gov Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT01534143CT.gov High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | — | Terminated | — | — | — |
NCT01415882CT.gov Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | — | Completed | — | — | — |
NCT01539083CT.gov Velcade (Bortezomib) Consolidation After Transplant | — | Completed | — | — | — |
NCT01518465CT.gov Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma | — | Terminated | — | — | — |
NCT01393964CT.gov Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function | — | Completed | — | — | — |
NCT01549431CT.gov Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01745640CT.gov Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) | — | Completed | — | — | — |
NCT01501370CT.gov Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy | — | Withdrawn | — | — | — |
NCT01485835CT.gov A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01349569CT.gov Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission | — | Completed | — | — | — |
NCT01337752CT.gov Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency | — | Completed | — | — | — |
NCT01502085CT.gov Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens | — | Completed | — | — | — |
NCT01329289CT.gov SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01428492CT.gov Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT01478048CT.gov Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01432600CT.gov Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide | — | Completed | — | — | — |
NCT01464034CT.gov A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01383928CT.gov Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01464112CT.gov A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT01212952CT.gov Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01359657CT.gov Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01335399CT.gov Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT01348919CT.gov Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01394354CT.gov Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01402284CT.gov Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01346787CT.gov Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01421186CT.gov A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01055301CT.gov S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01266811CT.gov A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01335685CT.gov Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01239797CT.gov Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01470131CT.gov A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01297764CT.gov A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT01311687CT.gov A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study | — | Completed | — | — | — |
NCT02556905CT.gov A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea | — | Completed | — | — | — |
NCT01303965CT.gov Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | — | Terminated | — | — | — |
NCT01237249CT.gov Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | — | Completed | — | — | — |
NCT01163357CT.gov Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | — | Completed | — | — | — |
NCT01208766CT.gov Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01248923CT.gov A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01217957CT.gov A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01237951CT.gov High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma | — | Completed | — | — | — |
NCT01183949CT.gov Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | — | Completed | — | — | — |
NCT01215344CT.gov First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | — | Completed | — | — | — |
NCT00568880CT.gov Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01328236CT.gov Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia | — | Unknown | — | — | — |
NCT01078441CT.gov Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | — | Terminated | — | — | — |
NCT01159574CT.gov Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma | — | Completed | — | — | — |
NCT01204164CT.gov Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies | — | Completed | — | — | — |
NCT01080391CT.gov Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT02559154CT.gov Modified Bortezomib-based Combination Therapy for Multiple Myeloma | — | Unknown | — | — | — |
NCT01164709CT.gov Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer | — | Completed | — | — | — |
NCT01249690CT.gov Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT01083602CT.gov Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01168804CT.gov Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01155583CT.gov Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01102426CT.gov Aplidin - Dexamethasone in Relapsed/Refractory Myeloma | — | Completed | — | — | — |
NCT01242267CT.gov Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT | — | Completed | — | — | — |
NCT01009840CT.gov IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01109004CT.gov Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | — | Completed | — | — | — |
NCT01554852CT.gov Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients | — | Unknown | — | — | — |
NCT01045681CT.gov Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01057225CT.gov Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | — | Completed | — | — | — |
NCT01090089CT.gov Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma | — | Completed | — | — | — |
NCT01114048CT.gov Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) | — | Unknown | — | — | — |
NCT01063907CT.gov A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01034553CT.gov Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01038388CT.gov A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02858999CT.gov Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 | — | Completed | — | — | — |
NCT01023308CT.gov Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT01002248CT.gov Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT00932698CT.gov Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | — | Completed | — | — | — |
NCT01093196CT.gov Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01010243CT.gov Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial | — | Unknown | — | — | — |
NCT01160484CT.gov Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01029054CT.gov Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00966693CT.gov Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03402295CT.gov Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation | — | Completed | — | — | — |
NCT00925821CT.gov Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00903968CT.gov Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00902915CT.gov Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure | — | Unknown | — | — | — |
NCT00698776CT.gov Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma | — | Completed | — | — | — |
NCT00920556CT.gov A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT00871013CT.gov Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT00858234CT.gov Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | — | Completed | — | — | — |
NCT00839956CT.gov Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant | — | Completed | — | — | — |
NCT00790842CT.gov Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction | — | Terminated | — | — | — |
NCT00872521CT.gov A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00821249CT.gov A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01530594CT.gov Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00773747CT.gov Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | — | Completed | — | — | — |
NCT00693433CT.gov Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00773838CT.gov Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | — | Completed | — | — | — |
NCT00849251CT.gov Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT01255514CT.gov Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00869232CT.gov UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | — | Active Not Recruiting | — | — | — |
NCT00744354CT.gov Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00729118CT.gov Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00765102CT.gov Trial of Romidepsin and Bortezomib for Multiple Myeloma | — | Terminated | — | — | — |
NCT00750815CT.gov Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT00689936CT.gov Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00687674CT.gov Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00720785CT.gov Natural Killer Cells and Bortezomib to Treat Cancer | — | Completed | — | — | — |
NCT00691704CT.gov Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy | — | Completed | — | — | — |
NCT00742404CT.gov Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT00708292CT.gov A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT00719901CT.gov Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00734877CT.gov UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | — | Active Not Recruiting | — | — | — |
NCT00833833CT.gov MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00729638CT.gov RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00664898CT.gov A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00724568CT.gov Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00609817CT.gov Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | — | Terminated | — | — | — |
NCT00603447CT.gov Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT00560391CT.gov Dasatinib in Combination With Revlimid (and Dexamethasone) | — | Completed | — | — | — |
NCT00532675CT.gov Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | — | Completed | — | — | — |
NCT00574288CT.gov Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma | — | Completed | — | — | — |
NCT00910897CT.gov Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) | — | Unknown | — | — | — |
NCT00639002CT.gov A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00642954CT.gov Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | — | Completed | — | — | — |
NCT00560352CT.gov Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | — | Terminated | — | — | — |
NCT00546780CT.gov A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse | — | Completed | — | — | — |
NCT01042704CT.gov Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT00670631CT.gov Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | — | Completed | — | — | — |
NCT00792142CT.gov Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | — | Completed | — | — | — |
NCT00617591CT.gov Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT00555906CT.gov An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. | — | Completed | — | — | — |
NCT00538824CT.gov Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00536575CT.gov Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00558896CT.gov CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis | — | Completed | — | — | — |
NCT00602511CT.gov Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma | — | Completed | — | — | — |
NCT00538733CT.gov Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00531453CT.gov A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00608907CT.gov An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | — | Completed | — | — | — |
NCT00531284CT.gov Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | — | Completed | — | — | — |
NCT00525447CT.gov Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00507442CT.gov Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00514371CT.gov A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00504101CT.gov Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | — | Withdrawn | — | — | — |
NCT00507416CT.gov Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone | — | Completed | — | — | — |
NCT00483262CT.gov Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00577512CT.gov 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE | — | Completed | — | — | — |
NCT00577668CT.gov A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) | — | Withdrawn | — | — | — |
NCT00398515CT.gov Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | — | Completed | — | — | — |
NCT00445692CT.gov Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | — | Completed | — | — | — |
NCT00445484CT.gov Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01532856CT.gov Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years | — | Unknown | — | — | — |
NCT00652041CT.gov Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT00415064CT.gov Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00401843CT.gov A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00431990CT.gov A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | — | Unknown | — | — | — |
NCT00572169CT.gov UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | — | Active Not Recruiting | — | — | — |
NCT00458705CT.gov Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00871910CT.gov Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | — | Completed | — | — | — |
NCT00402181CT.gov An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00573391CT.gov Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 | — | Terminated | — | — | — |
NCT00368121CT.gov EMMA-1 (Erbitux for Multiple Myeloma) | — | Terminated | — | — | — |
NCT00438841CT.gov Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma | — | Unknown | — | — | — |
NCT00401011CT.gov Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00574080CT.gov UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | — | Terminated | — | — | — |
NCT01370434CT.gov Two Cycles of PAD Combination by AHCT in MM | — | Completed | — | — | — |
NCT00523848CT.gov Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma | — | Completed | — | — | — |
NCT01134484CT.gov VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) | — | Unknown | — | — | — |
NCT00315757CT.gov Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00461747CT.gov GEM05 for Patients With Multiple Myeloma Under 65 Years | — | Completed | — | — | — |
NCT00401804CT.gov Bortezomib-Dexamethasone-Doxorubicin-Study | — | Completed | — | — | — |
NCT00452569CT.gov Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00334932CT.gov Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | — | Unknown | — | — | — |
NCT00263484CT.gov Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma | — | Completed | — | — | — |
NCT00375791CT.gov Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00319865CT.gov PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT00561743CT.gov A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00310024CT.gov Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00111813CT.gov Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | — | Completed | — | — | — |
NCT00150462CT.gov Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT00243035CT.gov Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | — | Terminated | — | — | — |
NCT00124579CT.gov S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00391157CT.gov VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma | — | Completed | — | — | — |
NCT00256776CT.gov MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation | — | Terminated | — | — | — |
NCT00148317CT.gov Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma | — | Completed | — | — | — |
NCT00116961CT.gov Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | — | Completed | — | — | — |
NCT00258245CT.gov Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | — | Completed | — | — | — |
NCT00229203CT.gov A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00131261CT.gov Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | — | Completed | — | — | — |
NCT00097981CT.gov A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00151203CT.gov Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00098475CT.gov Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT00358020CT.gov Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00293384CT.gov Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant | — | Completed | — | — | — |
NCT00287872CT.gov Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00153933CT.gov Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00054158CT.gov Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00135187CT.gov Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | — | Completed | — | — | — |
NCT00201695CT.gov Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT00088855CT.gov Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT00227682CT.gov Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00082784CT.gov Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | — | Completed | — | — | — |
NCT00581919CT.gov Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma | — | Completed | — | — | — |
NCT00064337CT.gov S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | — | Completed | — | — | — |
NCT00093028CT.gov Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | — | Completed | — | — | — |
NCT00075829CT.gov Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) | — | Completed | — | — | — |
NCT01296503CT.gov Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma | — | Completed | — | — | — |
NCT00089453CT.gov Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | — | Completed | — | — | — |
NCT00337506CT.gov Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | — | Terminated | — | — | — |
NCT00182663CT.gov Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant | — | Completed | — | — | — |
NCT00215943CT.gov Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | — | Terminated | — | — | — |
NCT01070862CT.gov Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. | — | Completed | — | — | — |
NCT00622336CT.gov A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT00056160CT.gov CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT00424047CT.gov A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT00635154CT.gov Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma | — | Completed | — | — | — |
NCT00222105CT.gov A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life | — | Completed | — | — | — |
NCT00049374CT.gov Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00580372CT.gov UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00040937CT.gov S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00089167CT.gov Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis | — | Completed | — | — | — |
NCT00033332CT.gov Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01341262CT.gov THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT00083460CT.gov Study of Combination PS-341 and Thalidomide in Multiple Myeloma | — | Completed | — | — | — |
NCT00577096CT.gov Effects of Exercise in Combination With Epoetin Alfa | — | Completed | — | — | — |
NCT00023530CT.gov Blood and Marrow Transplant Clinical Research Network | — | Completed | — | — | — |
NCT02288741CT.gov Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy | — | Completed | — | — | — |
NCT00083915CT.gov DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | — | Completed | — | — | — |
NCT00028886CT.gov Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT00006184CT.gov Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | — | Completed | — | — | — |
NCT00083538CT.gov Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | — | Completed | — | — | — |
NCT00017069CT.gov Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma | — | Terminated | — | — | — |
NCT00017602CT.gov Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00005987CT.gov Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT00008242CT.gov Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00038090CT.gov Thalidomide-Dexamethasone for Multiple Myeloma | — | Completed | — | — | — |
NCT00005834CT.gov S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00560053CT.gov Pethema Multiple Myeloma 2000 | — | Completed | — | — | — |
NCT00021359CT.gov Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00003493CT.gov Combination Chemotherapy in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00083551CT.gov UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | — | Completed | — | — | — |
NCT00083681CT.gov DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | — | Completed | — | — | — |
NCT00083902CT.gov Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy | — | Completed | — | — | — |
NCT00003603CT.gov Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT00002878CT.gov Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00002849CT.gov S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | — | Completed | — | — | — |
NCT00006232CT.gov Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma | — | Completed | — | — | — |
NCT00003007CT.gov Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma | — | Completed | — | — | — |
NCT00002548CT.gov SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | — | Completed | — | — | — |
NCT02666209CT.gov Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | — | No Longer Available | — | — | — |
NCT02658396CT.gov GO-203-2C + Bortezomib For Relapsed Or Refractory MM | — | Withdrawn | — | — | — |
NCT02856438CT.gov Early Patient Access Treatment Use Protocol CA204-220 | — | No Longer Available | — | — | — |
NCT00995059CT.gov Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03763370CT.gov Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma | — | Available | — | — | — |
NCT04534322CT.gov Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma | — | Approved For Marketing | — | — | — |
NCT00112879CT.gov Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01250808CT.gov Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | — | Available | — | — | — |
NCT05238311CT.gov Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | — | No Longer Available | — | — | — |
NCT02368301CT.gov Expanded Access Treatment Protocol CA204-143 | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Universitätsklinikum Hamburg-Eppendorf | Approved | BB · 69 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-plasma-cell-myeloma-213
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →